Packing batteries with more punch
Indian researchers are working on cells that can store more energy, last longer
Days after AstraZeneca resumed trials on the AZ-Oxford University vaccine candidate against Covid-19, clinical trials will resume in India as well. The Drug Controller General of India (DCGI) has given its green signal to Serum Institute of India to resume trials on the Covid-19 vaccine candidate, with greater attention on screening and monitoring for adverse events.
The vaccine trial had been paused in India after AZ had done the same globally, following an adverse event that was reported in one trial participant in the United Kingdom.
AZ resumed trials after the UK’s Medicines Health Regulatory Authority (MHRA) confirmed it was safe to do so.
However, trials on the AZ-Oxford candidate are yet to resume in the United States, and reports suggest that US authorities were investigating the adverse event that had been reported in the UK. A source-based report indicated that approvals to resume the trial may not come in till mid next week.
AZ and Oxford University have not revealed the nature of the adverse event, though reports have linked it to transverse myelitis, an inflammation of the spinal cord that could lead to paralysis, bladder, bowel dysfunction. In fact, voices from the clinical research community have called for greater transparency on trial details, given the public funds invested and government support behind fast-tracking the trial.
The company’s chief had briefed the investor community after the adverse event had required halting the vaccine trial. But global scientific voices have urged AZ to be more public with details on the trial and adverse event in the interest of greater trust in clinical research, especially since timelines on the vaccine-development have been shortened. Less transparency could lead to people having less confidence in taking the vaccine, they cautioned.
About 100 people have already been given the first shot of the two-dose vaccine, and the trial had been paused for seven days as the DCGI wanted safety to be reviewed, a person familiar with the development told Business Line. The AZ adverse-event-linked pause coincided with this period, the person said.
The DCGI approval to resume trials echoes the MHRA’s directive on greater scrutiny and screening, the source said. The second dose of the vaccine-probable would be given after a 28-period gap from the first shot. And 28 days after the second dose, blood samples of the volunteers in the trial would be screened.
A total of 1,700 persons would be recruited for the trial from 17 centres, the source said, adding that the trial would take about three to four months.
Indian researchers are working on cells that can store more energy, last longer
To fix a broken bone, doctors often harvest another bone from the patient’s body or from someone else. It ...
Superconductors from IIScScientists at IISc Bangalore have invented a device with a nanocrystal structure ...
Engineering and construction giant L&T has won a licence from the Council of Scientific & Industrial ...
Option price falls more than it rises for the same change in underlying
A long-term vacation here is worth a check-in
The fund delivered a return of 31.5% in 2020 compared with the category’s 15.5%
Care Health Insurance’s new rider offers no great benefit. We review its pros and cons
In these isolated times when people yearn for a slice of the familiar, amateur and professional chefs are ...
Given the events in Washington DC on January 6, this week’s quiz is all about buildings that house or housed ...
While good writing wars against the cliché, television gives it a natural home
India is ready with two vaccines to beat the deadliest virus of recent times. The immunisation drive, however, ...
Digital is becoming dominant media, but are companies and their ad agencies transforming fast enough to make a ...
Slow Network, promoted by journalist-lyricist Neelesh Misra, pushes rural products and experiences
How marketers can use the traditional exchange of festive wishes meaningfully
For Fortune, a brand celebrating its 20th anniversary, it was a rude shock to become the butt of social media ...
Three years after its inception, compliance with GST procedures remains a headache for exporters, job workers ...
Corporate social responsibility (CSR) initiatives of companies are altering the prospects for wooden toys of ...
Aequs Aerospace to create space for large-scale manufacture of toys at Koppal
And it has every reason to smile. Covid-19 has triggered a consumer shift towards branded products as ...
Please Email the Editor